According to Psychiatric News (6/27), for the first time, the FDA has “issued draft guidance on conducting clinical trials with psychedelic substances such as psilocybin and MDMA (ecstasy).” The agency now “invites professional feedback to the draft guidance by August 25 to ensure consideration.” The draft guidance document was posted to the FDA’s website.
Related Links:
— “FDA Issues Draft Guidance for Conducting Clinical Trials With Psychedelic Substances,” Psychiatric News, June 27, 2023